why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Drug FDA Status

Showing 70 of 139 result(s) (Page 7 of 14)
Drug Name: Voranigo

Active Ingredient: vorasidenib

Approval Date: 2024-08-06

Description: To treat Grade 2 astrocytoma or oligodendroglioma
Drug Trials Snapshot

Drug Name: Leqselvi

Active Ingredient: deuruxolitinib

Approval Date: 2024-07-25

Description: To treat severe alopecia areata
Drug Trials Snapshot

Drug Name: Kisunla

Active Ingredient: donanemab-azbt

Approval Date: 2024-07-02

Description: To treat Alzheimer’s disease
Drug Trials Snapshot

Drug Name: Ohtuvayre

Active Ingredient: ensifentrine

Approval Date: 2024-06-26

Description: To treat chronic obstructive pulmonary disease
Drug Trials Snapshot

Drug Name: Piasky

Active Ingredient: crovalimab-akkz

Approval Date: 2024-06-20

Description: To treat paroxysmal nocturnal hemoglobinuria
Drug Trials Snapshot

Drug Name: Sofdra

Active Ingredient: sofpironium

Approval Date: 2024-06-18

Description: To treat primary axillary hyperhidrosis
Drug Trials Snapshot

Drug Name: Iqirvo

Active Ingredient: elafibranor

Approval Date: 2024-06-10

Description: To treat primary biliary cholangitis in combination with ursodeoxycholic acid
Drug Trials Snapshot

Drug Name: Rytelo

Active Ingredient: imetelstat

Approval Date: 2024-06-06

Description: To treat low- to intermediate-1 risk myelodysplastic syndromes
Drug Trials Snapshot

Drug Name: Imdelltra

Active Ingredient: tarlatamab-dlle

Approval Date: 2024-05-16

Description: To treat extensive stage small cell lung cancer
Drug Trials Snapshot

Drug Name: Xolremdi

Active Ingredient: mavorixafor

Approval Date: 2024-04-26

Description: To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)
Drug Trials Snapshot

300×250 Ad Slot